693 related articles for article (PubMed ID: 3331044)
1. Imipenem/cilastatin versus amikacin plus piperacillin in the treatment of infections in neutropenic patients: a prospective, randomized multi-clinic study.
Norrby SR; Vandercam B; Louie T; Runde V; Norberg B; Anniko M; Andrien F; Baudrihaye M; Bow E; Burman LA
Scand J Infect Dis Suppl; 1987; 52():65-78. PubMed ID: 3331044
[TBL] [Abstract][Full Text] [Related]
2. Imipenem/cilastatin versus aminoglycoside plus amoxicillin plus clindamycin in the treatment of serious postoperative infections.
Christen D; Buchmann P; Geroulanos S
Scand J Infect Dis Suppl; 1987; 52():11-4. PubMed ID: 3331039
[TBL] [Abstract][Full Text] [Related]
3. A double beta-lactam combination versus an aminoglycoside-containing regimen as empiric antibiotic therapy for febrile granulocytopenic cancer patients.
De Jongh CA; Joshi JH; Thompson BW; Newman KA; Finley RS; Moody MR; Salvatore PC; Tenney JH; Drusano GL; Schimpff SC
Am J Med; 1986 May; 80(5C):101-11. PubMed ID: 3521269
[TBL] [Abstract][Full Text] [Related]
4. Treatment of febrile episodes in neutropenic leukemic patients with the antibiotic combinations piperacillin or ceftazidime plus amikacin: results of a randomized study.
Fenu S; Raccah R; Santilli S; Micozzi A; Girmena C; Martino P; Avvisati G
Chemioterapia; 1988 Oct; 7(5):323-6. PubMed ID: 3066517
[TBL] [Abstract][Full Text] [Related]
5. [Cefmenoxime or piperacillin plus amikacin. A prospective randomized comparison of empiric antibiotic therapy of febrile granulocytopenic cancer patients].
Sampi K; Kumai R; Maseki N; Sakurai M; Kaneko Y; Hattori M
Gan To Kagaku Ryoho; 1987 Mar; 14(3 Pt 1):674-9. PubMed ID: 3469935
[TBL] [Abstract][Full Text] [Related]
6. Imipenem/cilastatin therapy for serious infections in neonates and infants.
Nalin DR; Jacobsen CA
Scand J Infect Dis Suppl; 1987; 52():46-55. PubMed ID: 3331042
[TBL] [Abstract][Full Text] [Related]
7. Imipenem/cilastatin for pediatric infections in hospitalized patients.
Nalin DR; Hart CB; Shih WJ; Aziz MA
Scand J Infect Dis Suppl; 1987; 52():56-64. PubMed ID: 3331043
[TBL] [Abstract][Full Text] [Related]
8. Clinical trial of imipenem/cilastatin in severely burned and infected patients.
Culbertson GR; McManus AT; Conarro PA; McManus WF; Mason AD; Pruitt BA
Surg Gynecol Obstet; 1987 Jul; 165(1):25-8. PubMed ID: 3109046
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and tolerability of imipenem-cilastatin versus ceftazidime plus tobramycin as empiric therapy of presumed bacterial infection in neutropenic cancer patients.
Miller JA; Butler T; Beveridge RA; Kales AN; Binder RA; Smith LJ; Ueno WM; Milkovich G; Goldwater S; Marion A
Clin Ther; 1993; 15(3):486-99. PubMed ID: 8364941
[TBL] [Abstract][Full Text] [Related]
10. Piperacillin plus amikacin versus cefotaxime plus amikacin in neutropenic and feverish patients with malignant hemopathies.
Pavone V; Specchia G; Guarini A; Coniglio M; Iaculli L; Girardi F; Colucci A; Liso V
Chemioterapia; 1988 Oct; 7(5):330-5. PubMed ID: 3224402
[TBL] [Abstract][Full Text] [Related]
11. Intramuscular imipenem/cilastatin for treatment of mild and moderately severe bacterial infections.
Keller CA; Villavicencio J; Ramirez C
Scand J Infect Dis Suppl; 1987; 52():26-31. PubMed ID: 3483287
[TBL] [Abstract][Full Text] [Related]
12. A prospective, controlled, randomized, non-blind, comparative study of the efficacy and safety of a once daily high dose of ceftriaxone plus ciprofloxacin versus thrice daily ceftazidime plus amikacin in empirical therapy for febrile neutropenic patients.
Metallidis S; Kollaras P; Giannakakis T; Seitanidis B; Kordosis T; Nikolaidis J; Hatzitolios A; Nikolaidis P
Eur J Intern Med; 2008 Dec; 19(8):619-24. PubMed ID: 19046729
[TBL] [Abstract][Full Text] [Related]
13. Meropenem plus amikacin versus piperacillin-tazobactam plus netilmicin as empiric therapy for high-risk febrile neutropenia in children.
Aksoylar S; Cetingül N; Kantar M; Karapinar D; Kavakli K; Kansoy S
Pediatr Hematol Oncol; 2004 Mar; 21(2):115-23. PubMed ID: 15160510
[TBL] [Abstract][Full Text] [Related]
14. [Imipenem/cilastatin versus ceftazidime-amikacin in the treatment of febrile neutropenic patients].
Pérez C; Sirham M; Labarca J; Grebe G; Lira P; Oliva J; Duhalde M; Ocqueteau M; Acuña G
Rev Med Chil; 1995 Mar; 123(3):312-20. PubMed ID: 8525170
[TBL] [Abstract][Full Text] [Related]
15. Imipenem/cilastatin therapy of serious infections: a U.S. multicenter noncomparative trial.
Calandra GB; Hesney M; Brown KR
Clin Ther; 1985; 7(2):225-38. PubMed ID: 3886144
[TBL] [Abstract][Full Text] [Related]
16. Imipenem/cilastatin versus piperacillin/tazobactam plus amikacin for empirical therapy in febrile neutropenic patients: results of the COSTINE study.
Sanz MA; Bermúdez A; Rovira M; Besalduch J; Pascual MJ; Nocea G; Sanz-Rodríguez C;
Curr Med Res Opin; 2005 May; 21(5):645-55. PubMed ID: 15969864
[TBL] [Abstract][Full Text] [Related]
17. Treatment of febrile neutropenic patients with cancer who require hospitalization: a prospective randomized study comparing imipenem and cefepime.
Raad II; Escalante C; Hachem RY; Hanna HA; Husni R; Afif C; Boktour MR; Whimbey EE; Kontoyiannis D; Jacobson K; Kantarjian H; Levett LM; Rolston KV
Cancer; 2003 Sep; 98(5):1039-47. PubMed ID: 12942573
[TBL] [Abstract][Full Text] [Related]
18. Imipenem/cilastatin in the treatment of severe hospital infections.
Patoia L; Menichetti F; Bucaneve G; Pasticci MB; Baratta E; Grignani F; Del Favero A
Chemioterapia; 1988 Apr; 7(2):105-8. PubMed ID: 3165056
[TBL] [Abstract][Full Text] [Related]
19. Piperacillin/tazobactam versus imipenem/cilastatin in the treatment of intra-abdominal infections.
Niinikoski J; Havia T; Alhava E; Pääkkönen M; Miettinen P; Kivilaakso E; Haapiainen R; Matikainen M; Laitinen S
Surg Gynecol Obstet; 1993 Mar; 176(3):255-61. PubMed ID: 8382381
[TBL] [Abstract][Full Text] [Related]
20. Monotherapy with meropenem versus combination therapy with piperacillin plus amikacin as empiric therapy for neutropenic fever in children with lymphoma and solid tumors.
Düzova A; Kutluk T; Kanra G; Büyükpamukçu M; Akyüz C; Seçmeer G; Ceyhan M
Turk J Pediatr; 2001; 43(2):105-9. PubMed ID: 11432485
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
